UGA Biopharma GmbH is a research and development organization founded in 2009 and located in Hennigsdorf near Berlin. With an international team of experts, the company specializes in the development of monoclonal cell lines to produce biologics and biosimilars.
UGA Biopharma supports its customers across the entire development value chain, from cell line development and bioprocess design to the development of purification and analytical methods. The company tailors its services to customers’ specific requirements and delivers customized, high-quality solutions. In addition, UGA offers ready-to-use (R2U) cell lines for the expression of biosimilar candidates, as well as its proprietary CHO Prime® feed and media platform for cell culture applications.
UGA Biopharma’s customers have successfully utilized its products in clinical trials and achieved the corresponding market approvals.
We are currently looking to strengthen our highly motivated team as soon as possible.